UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 


 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): May 24, 2012

 

ARTHROCARE CORPORATION

(Exact name of registrant as specified in its charter)

 

Delaware

 

0-027422

 

94-3180312

(State or other jurisdiction
of Incorporation)

 

(Commission File Number)

 

(I.R.S. Employer Identification
No.)

 

7000 West William Cannon, Building One

Austin, TX 78735

(Address of principal executive offices, including zip code)

 

(512) 391-3900

(Registrant’s telephone number, including area code)

 

 

(Former name or former address, if changed since last report)

 


 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

 

o            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 



 

Item 5.07 Submission of Matters to a Vote of Security Holders

 

At the Company’s Annual Meeting of Shareholders held on May 24, 2012, shareholders voted on three proposals and cast their votes as follows:

 

1.              Election of Directors:

 

 

 

 

 

Votes

 

Broker

 

Name

 

Votes For

 

Withheld

 

Non-Votes

 

Christian P. Ahrens

 

27,802,402

 

234,445

 

3,450,945

 

Gregory A. Belinfanti

 

27,918,773

 

118,074

 

3,450,945

 

Barbara D. Boyan, Ph.D.

 

27,802,005

 

234,842

 

3,450,945

 

David Fitzgerald

 

27,407,905

 

628,942

 

3,450,945

 

James G. Foster

 

27,918,333

 

118,514

 

3,450,945

 

Terrence E. Geremski

 

27,919,213

 

117,634

 

3,450,945

 

Tord B. Lendau

 

27,386,675

 

650,172

 

3,450,945

 

Peter L. Wilson

 

27,270,492

 

766,355

 

3,450,945

 

 

2.              Advisory vote on the Company’s executive compensation:

 

 

 

Votes

 

 

 

Broker Non-

 

Votes For

 

Against

 

Abstentions

 

Votes

 

26,993,277

 

422,706

 

620,864

 

3,450,945

 

 

3.              Ratification of appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for 2012:

 

 

 

Votes

 

 

 

Votes For

 

Against

 

Abstentions

 

30,899,557

 

573,844

 

14,391

 

 

Item 7.01 — Regulation FD Disclosure

 

On May 25, 2012, Jean Woloszko, our Chief Technology Officer and Senior Vice President of Research and Development, entered into a new prearranged trading plan to sell 97,535 shares of ArthroCare common stock in one or more open market transactions between June 30, 2012 and May 20, 2013.

 

2



 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

ARTHROCARE CORPORATION

 

 

 

 

 

 

Date:  May 29, 2012

 

 

 

 

 

 

 

 By:

/s/ David Fitzgerald

 

 

David Fitzgerald

 

 

President and Chief Executive Officer

 

3